The effectiveness of virtual reality for rehabilitation of Parkinson disease: an overview of systematic reviews with meta-analyses

Yaqin Lu, Yonggui Ge, Wanqiang Chen, Wenting Xing, Lushan Wei, Caixia Zhang and Yusheng Yang*

Abstract

Background: An increasing number of systematic reviews (SRs) and meta-analyses (MAs) of clinical trials have begun to investigate the effects of virtual reality (VR) in patients with Parkinson disease (PD). The aim of this overview was to systematically summarize the current best evidence for the effectiveness of VR therapy for the rehabilitation of people with PD.

Methods: We searched SR-MAs based on randomized controlled trials (RCTs) for relevant literature in PubMed, Embase, and Cochrane library databases for systematic reviews from inception to December 5, 2020, and updated to January 26, 2022. The methodological quality of included SR-MAs was evaluated with the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2), and the certainty of evidence for outcomes with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE). We created an evidence map using a bubble plot format to represent the evidence base in 5 dimensions: effect size of VR therapy versus active intervention (AT), clinical outcome area, number of trials, statistical significance, and certainty of evidence.

Results: From a total of 585 reports, 12 reviews were identified, of which only one was rated moderate quality, three were rated low quality, and eight were rated critically low quality by AMSTAR 2. Compared with AT, VR therapy induced increased benefits on stride/step length, balance, and neuropsychiatric symptoms. Compared with passive intervention (PT), VR therapy had greater effects on gait speed, stride/step length, balance, activities of daily living, and postural control in people with PD. Certainty of evidence varied from very low to moderate.

Conclusions: We found the methodological quality of the reviews was poor, and certainty of the most evidence within them was low to very low. We were therefore unable to conclude with any confidence that, in people with PD, VR therapy is harmful or beneficial for gait, balance, motor function, quality of life, activities of daily living, cognitive function, neuropsychiatric symptoms, and postural control. In the future, rigorous-designed, high-quality RCTs with larger sample sizes are needed to further verify the effectiveness of VR therapy in the treatment of PD.

Keywords: Virtual reality, Parkinson disease, Effectiveness, Overview, Systematic reviews, Meta-analyses

Background

Parkinson disease (PD) is the most common progressive neurodegenerative disease worldwide. PD prevalence is increasing with age and affects 1% of the population above 60 years [1]. It is estimated that by
around 2030, the number of PD patients in China will reach 5 million, accounting for about 50% of the total number of PD patients in the world [2]. PD is characterized by motor symptoms such as rest tremor, bradykinesia, rigidity, and postural instability, which affect gait, balance, and movement quality, leading to difficulty in performing basic daily activities and quality of life and placing a heavy burden on families and society [3]. Multidisciplinary input is increasingly recognized as important in PD management [4]. Currently, drugs and surgical approaches were the main treatments of PD. Clinically approved drug treatments for PD mainly include levodopa, dopaminergic receptor agonists, and monoamine oxidase-B inhibitors. Levodopa is considered as a “first line” drug, but the long-term use of it leads to many complications [5]. Deep brain stimulation may be an effective treatment in PD patients; however, clinical trials have shown that it may have cognitive and psychiatric side effects [6]. Conventional rehabilitation is considered as an adjuvant to pharmacological and surgical treatments for PD to improve many dysfunctions and self-care ability, even delay the progression of the disease.

Virtual reality (VR) has emerged as a promising technology for researching complex impairments in people with PD and for providing personalized rehabilitation [7]. This technology typically combines real-time motion detection within a virtual environment in the context of a (video)game. The user can perceive, feel, and interact with virtual environments, viewing an avatar (a character or graphical representation of the user) that mimics the user's movements [8] by multiple sensory channels such as sight, sound, and touch [9]. Immediate feedback about performance and success is provided both concurrently (during game play) and terminally (at the end of the game). VR therapy attempts to promote activity-dependent neuroplasticity and motor learning [10, 11]. Recently, numerous systematic reviews (SRs) and meta-analyses (MAs) based on randomized controlled trials (RCTs) regarding the clinical effectiveness of VR therapy in the treatment of PD have been published. However, the overall results have remained mixed or inconclusive and their quality is uneven. An overview of SR-MAs is a relatively new method that aims to support clinical decision-making by synthesizing the findings, critically appraising the quality, and attempting to resolve discordant outcomes.

Therefore, we conducted an overview of SR-MAs to identify and summarize the existing evidence and to systematically determine the clinical effectiveness of using VR therapy to treat PD.

Methods
The overview was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [12] and the guidelines recommended by the Cochrane Collaboration [13]. The PRISMA checklist can be found in Additional file 1. The protocol was not prospectively registered.

Search strategy
We systematically searched PubMed, Embase, and Cochrane library databases for systematic reviews from inception to December 5, 2020, and updated to January 26, 2022. We used a combination of Medical Subject Headings with Entry Terms, or EMTREE with keywords as follows: Parkinson Disease, Virtual Reality Exposure Therapy, Virtual Reality, Exergaming, Systematic Review, and Meta-Analysis. In addition, to ensure a comprehensive data collection, references of relevant reviews were searched manually to identify additional eligible studies. The search strategy for the PubMed database is shown in Additional file 2.

Eligibility criteria
Types of reviews
In this overview, we have included SR-MAs of RCTs, and the full-text article was published in the English language. A review qualified as a SR-MA if, at a minimum, it had been conducted with systematic methods, an attempt was made to identify all of the relevant primary studies in at least one database and a search strategy was provided, and it performed a quality appraisal of the primary trials included and included quantitative syntheses. The reason for this is the fact that meta-analytical studies offer an effect estimate which would facilitate data analysis, but this was not the case for systematic reviews.

Types of participants
Participants involved in reviews were clinically definite diagnosis of PD and were defined by the UK Parkinson’s Disease Society Brain Bank or other diagnostic criteria. We had no restrictions on gender, age, drug dosage, duration, and severity of PD. We included reviews reporting an intervention carried out in a mixed sample of participants if data for participants with PD were provided separately.

Types of interventions
Intervention groups were VR-based rehabilitation interventions (with/without combined interventions). Control interventions needed to involve passive treatment (PT) or active treatment (AT) without a VR component. PT included either educational programs or a control group
receiving no intervention. AT involved usual care or any other exercise intervention without a VR component.

**Types of outcome measures**

The primary outcomes we collected included two aspects: (1) Gait. Gait speed, stride/step length, walking stability such as the Dynamic Gait Index (DGI) or Functional Gait Assessment (FGA), and walking distance such as the Two- or Six-Minute Walk Test (2MWT or 6MWT) were used to evaluate gait. (2) Balance function. Balance was assessed with Berg Balance Scale (BBS), Timed Up and Go test (TUG), Single-Leg Stance Test (SLS), or Mini-Balance Evaluation Systems Test (Mini-BESTest).

The secondary outcomes included the following: (1) Balance confidence. The Falls Efficacy Scale (FES), FES-international (FES-I), and Activities-specific Balance Confidence scale (ABC) were used to measure the patient's level of confidence in doing specific activities that could affect balance and cause falls. (2) Motor function. We used the Unified Parkinson's Disease Rating Scale (UPDRS) part III to address global motor function changes. (3) Quality of life. Quality of life was determined by the 39-Item Parkinson's Disease Questionnaire (PDQ-39), or its short form (PDQ-8), or the World Health Organization Quality of Life for Older Persons (WHO-QOL-OLD). (4) Activities of daily living. UPDRS part II and the modified Barthel Index (MBI) were employed to measure activities of daily living. (5) Cognitive function. Cognitive function was measured by Montreal Cognitive Assessment (MoCA), Digit Span forward (DSF), and Mini-Mental State Examination (MMSE). (6) Neuropsychiatric symptoms. Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Hamilton Depression Scale (HAM-D), Hospital Anxiety and Depression Scale (HADS), and 15-item Geriatric Depression Scale (GDS-15) were used to record neuropsychiatric symptom changes in subjects. (7) Postural control. Sensory organization test (SOT) was designed to examine the degree of postural control.

The exclusion criteria included the following: (1) studies which had mixed samples (PD, stroke, multiple sclerosis, cerebral palsy, or other neurological disorders) cannot extract data separately; (2) studies where PD patients all used VR without control group or control group was healthy individuals; (3) studies where PD patients with different symptoms (freezers vs. non-freezers) underwent the same VR therapy; and (4) non-systematic reviews, guidelines, conference abstracts, surveys, commentaries, editorials, letters, and notes.

**Study selection**

All titles and abstracts were initially screened by two independent investigators (L.Y.Q and G.Y.G) after automatically removing duplicate results to identify potentially relevant studies for inclusion. At this stage, we excluded studies that were not focused on the effects of VR therapy on PD patients or not described as SR-MAs. Furthermore, full-text articles were reviewed and selected according to eligibility criteria. We excluded reviews that did not present summary statistics for outcomes (effect size with 95% CIs). Final relevant studies were shortlisted. In case of discrepancies, a consensus was achieved by discussion. If consensus could not be reached, a third reviewer (Y.Y.S) was consulted.

**Data extraction**

Two investigators (L.Y.Q and G.Y.G) extracted the following basic characteristics from each eligible review: the first author, publication year, country of the review author, the number of included studies, sample size, interventions (experiment interventions and control interventions), outcomes of interest, quality assessment tools, and main conclusions. Differences between the review authors were settled by discussion, and a third reviewer (Y.Y.S) was consulted if differences persisted. The study authors were contacted with the aim of acquiring additional information on the data presented.

**Quality assessment**

Two independent investigators (L.Y.Q and G.Y.G) assessed the methodological quality of the SR-MAs and the certainty of evidence in the included SR-MA. We resolved discrepancies through discussion or, if needed, through arbitration by a third review author (Y.Y.S).

**Methodological quality of included SR-MAs**

The methodological quality of each included review was evaluated using the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2) tool [14]. AMSTAR-2 is a comprehensive critical appraisal tool for SRs/MAs of randomized and non-randomized studies that focuses on weaknesses in critical domains but not an overall score. The tool assesses 16 items, among which 7 are critical domains (items 2, 4, 7, 9, 11, 13, and 15). The evaluation is reduced to three options, “Yes,” “Partial Yes,” and “No.” AMSTAR-2 classifies the overall confidence on the results of the review into four levels: high, moderate, low, and critically low.

**Certainty of evidence in included SR-MAs**

We did not re-evaluate the certainty of the evidence for the main outcomes if the review author had already performed the assessment. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment from the pooled outcome...
data as assessed by authors in a particular systematic review. Where review authors did not undertake GRADE, we performed a new assessment ourselves. The GRADE scoring is judged by the risk of bias, inconsistency, imprecision, indirectness, and publication bias [15]. Results are divided into four levels: high, moderate, low, and very low.

**Statistical analysis**

We did not conduct novel analyses for this overview. We summarized the characteristics of included reviews as well as the AMSTAR-2 ratings for each separate review. We have presented comparisons for each primary and secondary outcome where possible. Comparisons of primary interest were as follows.

- VR therapy versus AT
- VR therapy versus PT
- VR therapy versus controls (mixed AT with PT)

We created a bubble plot to present evidence base using Microsoft office Excel 2016 software (Microsoft Corp, Redmond, WA, www.microsoft.com). Each bubble plot displayed information in 5 dimensions: effect size (standard mean difference (SMD) or mean difference (MD)) of VR therapy for PD patients (y-axis), clinical outcome area (x-axis), number of trials (bubble size), statistical significance (bubble pattern), and certainty of evidence (bubble color).

**Results**

**Search results**

A flow diagram of study screening and selection procedures is illustrated in Fig. 1. Our electronic search yielded 585 potentially relevant publications. After automatic removal of duplicates, 380 records were screened on the basis of the title or abstract. Of the remaining 46 reviews, 34 reviews were excluded: participants were not PD (n = 8), intervention was not VR (n = 1), SR-MAs were not based on RCTs (n = 8), conference abstracts only (n = 3),...
| Author (year) | Country | Trials (sample size) | Intervention | Outcomes | Quality assessment tool | Main conclusions |
|--------------|---------|----------------------|--------------|----------|------------------------|-----------------|
| Sarasso E (2021) [16] | Italy | 22 (901) | VR | AT | Gait speed  
Stride/step length  
Walking stability (DGI/FGA)  
Walking distance (6MWT)  
Balance (BBS)  
Balance (TUG)  
Balance confidence (ABC/FES/FES-I)  
Motor function (UPDRS-III)  
Quality of life (PDQ-39/PDQ-8) | Cochrane Collaboration's tool | Balance training in a VR setting is more effective than balance training to improve balance in PD subjects immediately after training. |
| Li R (2021) [17] | China | 22 (836) | VR | Both (mix AT with PT) | Balance (BBS)  
Quality of life (PDQ-39)  
Activities of daily living (MBI/UPDRS-II)  
Neuropsychiatric symptoms (HAM/D/HADS/GDS-15/BDI) | PEDro scale | Rehabilitation training based on VR significantly improved balance, quality of life, activities of daily living, and depressive symptoms compared to the control group. |
| Elena P (2021) [18] | Cyprus | 14 (548) | VR | AT | Walking stability (DGI)  
Balance (BBS)  
Balance (TUG)  
Balance confidence (ABC)  
Quality of life (PDQ-39)  
Activities of daily living (UPDRS-II) | PEDro scale | VR therapy related with improved quality of life, balance, and gait. |
| Triegaardt J (2020) [19] | UK | 10 (343) | VR | AT; PT | Gait speed  
Stride/step length  
Balance (BBS)  
Motor function (UPDRS-III)  
Cognitive function (MoCA)  
Activities of daily living (UPDRS-II)  
Quality of life (PDQ39/PDQ8) | Cochrane Collaboration's tool | Compared with AT, VR therapy led to greater improvement of stride length.  
Compared with PT, VR therapy had greater effects on gait speed, stride length, balance, and activities of daily living. |
| Marotta N (2020) [20] | Italy | 7 (236) | VR | Both (mix AT with PT) | Functional locomotion | Cochrane Collaboration's tool | VR therapy show immediate positive effects on functional locomotion in people with PD. |
| Lina C (2020) [21] | China | 12 (360) | VR | AT | Gait speed  
Balance (BBS)  
Motor function (TUG)  
Activities of daily living (MBI) | Cochrane Collaboration's tool | VR therapy may be valuable in improving the balance, gait speed, and ability to perform activities of daily living in patients with PD. |
| Chen Y (2020) [22] | China | 14 (574) | VR | AT | Walking stability (DGI/FGA)  
Balance (BBS)  
Balance (TUG)  
Balance confidence (ABC) | PEDro scale | Compared with AT, VR therapy improved the balance (BBS).  
There was no significant difference on balance (TUG), balance confidence, and walking stability between the VR therapy groups and the AT groups. |
Table 1 (continued)

| Author (year) | Country | Trials (sample size) | Intervention | Outcomes | Quality assessment tool | Main conclusions |
|---------------|---------|----------------------|--------------|----------|-------------------------|-----------------|
| Wang B (2019) [23] | China | 12 (419) | VR, AT | Gait speed, Stride/step length, Walking distance (6MWT), Balance (BBS), Balance (TUG) | PEDro scale | This review demonstrated significant improvements in balance and stride length in PD patients who received VR compared with controls. There was no significant difference in gait speed and walking distance. |
| Santos P (2019) [24] | Brasil | 5 (152) | VR, AT | Balance (BBS), Quality of life (PDQ-39) | PEDro scale | Combination VR and conventional physiotherapy was more effective on balance rehabilitation and quality of life of patients with PD. |
| Lei C (2019) [25] | China | 16 (555) | VR, AT | Gait speed, Stride/step length, Walking stability (DGI), Balance (BBS), Balance (TUG), Balance confidence (ABC/FES), Motor function (UPDRS-III), Activities of daily living (UPDRS-II), Quality of life (PDQ-39/WHOOQOL-OLD), Neuropsychiatric symptoms (BAI/BDI/HAMD), Cognitive function (DSF/MoCA) | Cochrane Collaboration's tool | VR performed better than AT in step/stride length, balance, balance confidence, quality of life, and neuropsychiatric symptoms. There was no effect on the gait speed, DGI, motor function, cognitive function, and activities of daily living. |
| Dockx K (2016) [26] | Belgium | 8 (263) | VR, AT, PT | Gait speed, Stride/step length, Balance (BBS), Balance (BBS/TUG/SLS), Quality of life (PDQ-39) | Cochrane Collaboration's tool | In comparison to AT, VR may lead to a moderate improvement in step and stride length. VR and physiotherapy may have similar effects on gait, balance, and quality of life. In comparison to PT, VR therapy elicited greater improvements in gait, balance, and quality of life. |
| Harris DM (2015) [27] | Japan | 2 (74) | VR, AT, PT | Balance (BBS), Postural control (SOT) | PEDro scale | With the current available studies, the efficacy of VR therapy cannot be sufficiently determined for people with PD. |

VR virtual reality, AT active intervention, PD Parkinson Disease, PEDro Physiotherapy Evidence Database, DGI Dynamic Gait Index, FGA Functional Gait Assessment, 6MWT 6-Minute Walking Test, BBS Berg Balance Scale, TUG Timed Up and Go test, ABC Activities-Specific Balance Confidence scale, FES Falls Efficacy Scale, FES-I FES-international, UPDRS-III Unified Parkinson Disease Rating Scale part III, PDQ-39 39-item Parkinson Disease Questionnaire, MBI modified Barthel Index, HADS Hospital Anxiety and Depression Scale, HAMID Hamilton Depression scale, GDS-15 15-item Geriatric Depression scale, BDI Beck Depression Inventory, WHOQOL-OLD World Health Organization Quality of Life Old, BAI Beck Anxiety Inventory, DSF Digit Span forward, MoCA Montreal Cognitive Assessment, SLS Single-Leg Stance Test, SOT sensory organization test.
systematic review without quantitative data syntheses \((n = 13)\), and full text was not English language \((n = 1)\). Finally, 12 SR-MAs \([16–27]\) met the inclusion criteria and were included in this overview.

**Study characteristics**
The characteristics of the 12 SR-MAs included in our final analysis are summarized in Table 1. All studies were published between 2015 and 2021. The number of apposite studies included in each review ranged from 2 to 22, and the sample sizes ranged from 74 to 901. All reviews reported the VR-based rehabilitation training (VR therapy) as interventions. Out of the eligible SR-MAs, seven \([16, 18, 21–25]\) included VR therapy versus AT as a comparison, two \([19, 26]\) included VR therapy versus AT or PT respectively as comparisons. Two reviews \([17, 20]\) did not classify the control group, which mixed AT with PT. In addition, one review \([27]\) presented two evidence syntheses that were derived from single studies respectively. Six SR-MAs \([16, 19–21, 25, 26]\) used the Cochrane Collaborations tool, and six SR-MAs \([17, 18, 22–24, 27]\) used the PEDro scale.

**Table 2 Result of the AMSTAR-2 assessments**

| Study           | AMSTAR-2-Q1 | AMSTAR-2-Q2 | AMSTAR-2-Q3 | AMSTAR-2-Q4 | AMSTAR-2-Q5 | AMSTAR-2-Q6 | AMSTAR-2-Q7 | AMSTAR-2-Q8 | AMSTAR-2-Q9 | AMSTAR-2-Q10 | AMSTAR-2-Q11 | AMSTAR-2-Q12 | AMSTAR-2-Q13 | AMSTAR-2-Q14 | AMSTAR-2-Q15 | AMSTAR-2-Q16 |
|-----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Sarasso E (2021) \[16\] | Y           | Y           | N           | Y           | Y           | Y           | N           | Y           | N           | Y           | N           | N           | N           | N           | N           | CL          |
| Li R (2021) \[17\] | Y           | Y           | N           | Y           | Y           | N           | N           | N           | N           | N           | Y           | Y           | N           | N           | N           | CL          |
| Elena P (2021) \[18\] | Y           | Y           | N           | PY          | Y           | Y           | N           | Y           | N           | Y           | N           | N           | N           | N           | N           | CL          |
| Triagegaard J (2020) \[19\] | Y           | N           | Y           | N           | N           | PY          | Y           | N           | Y           | Y           | Y           | Y           | N           | Y           | CL          |
| Marotta N (2020) \[20\] | Y           | N           | N           | PY          | Y           | N           | N           | N           | N           | Y           | N           | N           | N           | N           | CL          |
| Lina C (2020) \[21\] | Y           | N           | PY          | Y           | N           | PY          | Y           | N           | Y           | N           | Y           | N           | N           | N           | CL          |
| Chen Y (2020) \[22\] | Y           | N           | Y           | Y           | Y           | PY          | Y           | Y           | Y           | Y           | Y           | Y           | N           | L           |
| Wang B (2019) \[23\] | Y           | N           | Y           | Y           | Y           | PY          | Y           | N           | Y           | N           | Y           | Y           | Y           | L           |
| Santos P (2019) \[24\] | Y           | N           | PY          | Y           | Y           | N           | Y           | N           | Y           | N           | Y           | N           | N           | N           | CL          |
| Lei C (2019) \[25\] | Y           | Y           | Y           | PY          | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | M           |
| Dockx K (2016) \[26\] | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | Y           | N           | L           |
| Harris DM (2015) \[27\] | Y           | N           | Y           | Y           | Y           | Y           | N           | Y           | N           | Y           | N           | N           | N           | Y           | CL          |

Y: yes, PY: partial yes, N: no, CL: critically low, L: low, M: moderate, H: high

Q1: Did the research questions and inclusion criteria for the review include the components of PICO?
Q2: Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol?
Q3: Did the review authors explain their selection of the study designs for inclusion in the review?
Q4: Did the review authors use a comprehensive literature search strategy?
Q5: Did the review authors perform study selection in duplicate?
Q6: Did the review authors perform data extraction in duplicate?
Q7: Did the review authors provide a list of excluded studies and justify the exclusions?
Q8: Did the review authors describe the included studies in adequate detail?
Q9: Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review?
Q10: Did the review authors report on the sources of funding for the studies included in the review?
Q11: If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results?
Q12: If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis?
Q13: Did the review authors account for RoB in individual studies when interpreting/discussing the results of the review?
Q14: Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?
Q15: If they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?
Q16: Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Critical domains: Q2, Q4, Q7, Q9, Q11, Q13, and Q15. High: No or one non-critical weakness. Moderate: More than one non-critical weakness. Low: One critical flaw with or without non-critical weaknesses. Critically low: More than one critical flaw with or without non-critical weaknesses.
| Outcomes                  | Study                          | Effect estimation (95% CI) | Studies (participants) | Certainty of the evidence (GRADE) |
|--------------------------|-------------------------------|----------------------------|------------------------|-----------------------------------|
| Gait speed               | Sarasso E (2021) [16]         | MD 0.03 (−0.07, 0.07)      | 8 (279)                | Very low<sup>a,b,c</sup>          |
| Gait speed               | Triegaardt J (2020) [19]      | SMD 0.08 (−0.27, 0.44)     | 6 (209)                | Very low<sup>a,c</sup>            |
| Gait speed               | Lina C (2020) [21]            | MD 0.13 (0.02, 0.24)       | 4 (174)                | Very low<sup>a</sup>              |
| Gait speed               | Wang B (2019) [23]            | MD −0.08 (−0.06, 0.06)     | 5 (203)                | Very low<sup>a</sup>              |
| Gait speed               | Lei C (2019) [25]             | SMD 0.19 (−0.03, 0.40)     | 7 (347)                | Very low<sup>a,c</sup>            |
| Gait speed               | Dockx K (2016) [26]           | SMD 0.18 (−0.20, 0.57)     | 3 (186)                | Very low<sup>a,c</sup>            |
| Stride/step length       | Sarasso E (2021) [16]         | SMD 0.64 (0.25, 1.02)      | 4 (110)                | Very low<sup>a,b,c</sup>          |
| Stride/step length       | Triegaardt J (2020) [19]      | SMD 0.70 (0.32, 1.08)      | 4 (116)                | Very low<sup>a,b,c</sup>          |
| Stride/step length       | Wang B (2019) [23]            | MD 9.65 (4.31, 14.98)      | 2 (79)                 | Very low<sup>a,b</sup>            |
| Stride/step length       | Lei C (2019) [25]             | SMD 0.72 (0.40, 1.04)      | 4 (166)                | Very low<sup>a,b,c</sup>          |
| Walking stability (DGI)  | Dockx K (2016) [26]           | SMD 0.69 (0.30, 1.08)      | 3 (106)                | Very low<sup>a,b,c</sup>          |
| Walking stability (DGI)  | Elena P (2021) [18]           | MD 1.13 (0.35, 1.92)       | 3 (176)                | Very low<sup>a,b</sup>            |
| Walking distance (6MWT)  | Sarasso E (2021) [16]         | MD 8.20 (−17.28, 33.69)   | 3 (72)                 | Very low<sup>a,b</sup>            |
| Walking distance (6MWT)  | Wang B (2019) [23]            | MD 8.91 (−43.43, 61.13)   | 2 (45)                 | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Sarasso E (2021) [16]         | MD 2.09 (0.86, 3.33)       | 14 (410)               | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Elena P (2021) [18]           | MD 2.64 (0.45, 4.83)       | 7 (281)                | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Triegaardt J (2020) [19]      | MD 0.26 (−1.02, 0.62)      | 5 (166)                | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Lina C (2020) [21]            | MD 2.28 (1.39, 3.16)       | 9 (281)                | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Chen Y (2020) [22]            | MD 1.23 (0.15, 2.31)       | 8 (266)                | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Wang B (2019) [23]            | MD 2.69 (1.37, 4.02)       | 9 (299)                | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Santos P (2019) [24]          | MD 1.24 (0.24, 2.25)       | 3 (72)                 | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Lei C (2019) [25]             | SMD 0.22 (0.01, 0.42)      | 11 (360)               | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Dockx K (2016) [26]           | MD 0.55 (−0.48, 1.38)      | 3 (86)                 | Very low<sup>a,b</sup>            |
| Balance (BBS)            | Harris DA (2015) [27]         | SMD 0.12 (−0.58, 0.83)     | 1 (32)                 | Very low<sup>a,b</sup>            |
| Balance (TUG)            | Sarasso E (2021) [28]         | MD −1.55 (−3.06, −0.04)    | 8 (236)                | Very low<sup>a,b</sup>            |
| Balance (TUG)            | Elena P (2021) [18]           | MD −0.98 (−2.21, 0.26)     | 6 (205)                | Very low<sup>a,b</sup>            |
| Balance (TUG)            | Lina C (2020) [21]            | MD −1.66 (−2.74, −0.58)    | 7 (193)                | Very low<sup>a,b</sup>            |
| Balance (TUG)            | Chen Y (2020) [22]            | MD −0.18 (−1.37, 1.00)     | 4 (120)                | Very low<sup>a,b</sup>            |
| Balance (TUG)            | Wang B (2019) [23]            | MD −2.86 (−5.60, −0.12)    | 5 (144)                | Very low<sup>a,b</sup>            |
Table 3 (continued)

| Outcomes                               | Study                        | Effect estimation (95% CI) | Studies (participants) | Certainty of the evidence (GRADE) |
|----------------------------------------|------------------------------|---------------------------|------------------------|-----------------------------------|
| Balance (TUG)                          | Lei C (2019) [25]            | MD: −1.95 (−2.81, −1.08) | 7 (237)                | Very low                        |
| Balance (BBS/TUG/SLS)                  | Dockx K (2016) [26]          | SMD: 0.34 (−0.04, 0.71)  | 5 (155)                | Very low                        |
| Balance confidence (ABC)               | Elena P (2021) [18]          | MD: 7.03 (0.36, 13.69)   | 2 (115)                | Low                             |
| Balance confidence (ABC)               | Chen Y (2020) [22]           | MD: 1.69 (−2.62, 6.01)   | 2 (115)                | Very low                        |
| Balance confidence (ABC/FES/FES-I)     | Sarasso E (2021) [28]        | SMD: 0.08 (−0.15, 0.32)  | 7 (334)                | Very low                        |
| Balance confidence (ABC/FES)           | Lei C (2019) [25]            | MD: −0.73 (−1.43, 0.02)  | 3 (104)                | Very low                        |
| Motor function (UPDRS-III)             | Sarasso E (2021) [28]        | MD: −0.25 (−2.28, 1.79)  | 5 (164)                | Very low                        |
| Motor function (UPDRS-III)             | Triegaardt J (2020) [19]     | SMD: −0.38 (−1.45, 0.69) | 3 (75)                 | Very low                        |
| Motor function (UPDRS-III)             | Lei C (2019) [25]            | MD: −0.50 (−1.48, 0.48)  | 5 (164)                | Very low                        |
| Quality of life (PDQ-39)               | Elena P (2021) [18]          | MD: −1.21 (−1.68, −0.73) | 7 (207)                | Very low                        |
| Quality of life (PDQ-39)               | Santos P (2019) [24]         | MD: −8.98 (−15.22, −2.58) | 2 (56)                 | Moderate                        |
| Quality of life (PDQ-39)               | Dockx K (2016) [26]          | MD: 3.73 (−2.16, 9.61)   | 6 (106)                | Very low                        |
| Quality of life (PDQ-39/PDQ-8)         | Sarasso E (2021) [28]        | SMD: 0.12 (−0.10, 0.35)  | 9 (303)                | Very low                        |
| Quality of life (PDQ-39/PDQ-8)         | Triegaardt J (2020) [19]     | SMD: 0.20 (−0.16, 0.57)  | 5 (176)                | Very low                        |
| Quality of life (PDQ-39/WHOQOL-OLD)    | Lei C (2019) [25]            | SMD: −0.47 (−0.73, −0.22) | 6 (248)                | Very low                        |
| Activities of daily living (UPDRS-II)  | Elena P (2021) [18]          | MD: −2.37 (−5.97, 1.23)  | 3 (101)                | Very low                        |
| Activities of daily living (UPDRS-II)  | Triegaardt J (2020) [19]     | SMD: −0.13 (−0.82, 0.57) | 1 (32)                 | Very low                        |
| Activities of daily living (UPDRS-II)  | Lei C (2019) [25]            | SMD: 0.25 (−0.14, 0.64)  | 4 (103)                | Very low                        |
| Activities of daily living (MBI)       | Lina C (2020) [21]           | MD: 2.93 (0.80, 5.06)    | 2 (51)                 | Very low                        |
| Cognitive function (MoCA)              | Triegaardt J (2020) [19]     | SMD: 0.08 (−0.61, 0.78)  | 1 (32)                 | Very low                        |
| Cognitive function (DSF/MoCA)          | Lei C (2019) [25]            | SMD: 0.21 (−0.28, 0.69)  | 2 (68)                 | Very low                        |
| Neuropsychiatric symptoms (BAI/BDI/HAMD)| Lei C (2019) [25]            | SMD: −0.96 (−1.27, −0.65) | 4 (184)                | Very low                        |

Ci confidence intervals, GRADE Grading of Recommendations Assessment, Development and Evaluation, MD mean difference, SMD standard mean difference, DGI Dynamic Gait Index, FGA Functional Gait Assessment, 6-WMT 6-Minute Walking Test, BBS Berg balance scale, TUG Timed Up and Go test, SLS Single-Leg Stance Test, ABC Activities-Specific Balance Confidence scale, FES Falls Efficacy Scale, FES-FES-international, UPDRS-III Unified Parkinson Disease Rating Scale part III, PDQ-39 39-item Parkinson Disease Questionnaire, WHOQOL-OLD World Health Organization Quality of Life-Old, MBI modified Barthel index, MoCA Montreal Cognitive Assessment, DSF Digit Span forward, BAI Beck Anxiety Inventory, BDI Beck Depression Inventory, HAMD Hamilton Depression scale

GRADE Working Group grades of evidence—high certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

**a** High risk of bias in at least a half of studies included within the analysis, hence bias is highly likely. Therefore, the certainty of evidence was downgraded by two levels due to the methodological limitations (risk of bias).

**b** Substantial heterogeneity among trials (I² equal or more than 50%, equal or less than 90%). Therefore, the certainty of evidence was downgraded by one level (inconsistency).

**c** The total population size was small (<400). Therefore, the certainty of evidence was downgraded by one level (imprecision).

**d** High risk of bias in less than a half of studies included within the analysis, hence bias is highly likely. Therefore, the certainty of evidence was downgraded by one level due to the methodological limitations (risk of bias).

**e** Considerable heterogeneity among trials (I²>90%). Therefore, the certainty of evidence was downgraded by two levels (inconsistency).

**f** Different ways of assessment were used across studies. Therefore, the certainty of evidence was downgraded by one level (other consideration, large effect).

**g** The estimated effect was large reaching a plausible clinically relevant magnitude. Therefore, the certainty of evidence was upgraded by one level (other consideration, large effect).
of all the others [16–21, 24, 27] (66.7%) were critically low. The key factors affecting the quality of the literature included item 2 (only five reviews [16–18, 25, 26] had registered and had a protocol before performing the review), item 4 (seven reviews [16, 17, 19, 22, 23, 26, 27] used a comprehensive literature search strategy with searching references of relevant reviews or searching relevant gray literature), item 7 (two reviews [25, 26] provided a list of excluded studies and justified the exclusions), item 9 (all reviews [16–27] reported risk of bias use a satisfactory technique), item 11 (10 reviews [16, 18, 19, 21–27] conducted a statistical combination of results using appropriate methods), item 13 (all reviews [16–27] accounted for the risk of bias in the primary studies when interpreting the results of the reviews), and item 15 (three reviews [22, 23, 25] carried out an adequate investigation of publication bias study and discuss its impact on the review).

**Effect of interventions**

We found marked heterogeneity of the evaluated comparisons and measured outcomes among the included reviews. Various comparison modes in included reviews and key findings are summarized below.

**Comparison 1: VR therapy versus AT**

An overview of the review result summary is provided in Table 3. Figures 2 and 3 presented the evidence map of effectiveness for VR therapy compared to AT in the patients with PD.

Five reviews [16, 19, 23, 25, 26] reported the stride/step length and concluded that VR therapy had a greater improvement of stride/step length compared with AT. The balance function was assessed by Berg Balance Scale (BBS) and Timed Up and Go test (TUG) in ten [16, 18, 19, 21–27] and six [16, 18, 21–23, 25] reviews, respectively, and the majority (7/10, 4/6) indicated a significant difference between VR therapy and AT, whereby VR therapy was shown to be superior. Only one review [25] investigated the effect of VR therapy on neuropsychiatric symptoms and found a significant improvement \((SMD = -0.96, 95\% CI = -1.27 \text{ to } -0.65, \text{ very low-certainty evidence})\) compared with AT. The low to very low certainty of evidence across reviews means it was not possible to state whether more benefit of VR therapy on stride/step length, balance function, and neuropsychiatric symptoms when compared to AT.

The results regarding gait speed, walking stability, balance confidence, quality of life, and activities...
of daily living were mixed and provided no convincing evidence of the effect of VR therapy versus AT on these areas.

We found no significant difference between VR and AT on walking distance, motor function, and cognitive function. Most reviews described similar improvements in both exercise groups.

**Comparison 2: VR therapy versus PT**

An overview of the review result summary is provided in Table 4.

We found three reviews investigating VR therapy versus PT in participants with PD. Triegaardt et al. [19] reported that VR therapy had greater effects on gait speed, stride/step length, balance function, and activities of daily living compared with PT. Dockx et al. [26] showed a significant benefit of VR exercise on balance as a composite measure (SMD 1.02, 95% CI 0.38 to 1.65) compared to PT. The evidence [27] derived from a single study showed an improvement in postural control (SMD 2.57, 95% CI 1.53 to 3.60) after VR therapy. Given the moderate to very low certainty of the evidence and limited data, we were unable to make any conclusion on the effect of VR therapy versus PT on function in people with PD.

**Comparison 3: VR therapy versus controls (mixed AT and PT)**

One review [17] revealed that training significantly improved balance (g = 0.66, P < 0.001), quality of life (g = 0.28, P = 0.015), activities of daily living (g = 0.62, P < 0.001), and neuropsychiatric symptoms (g = 0.67, P = 0.021) compared to the control group. A second review [20] reported that Kinect and Wii showed immediate positive effects on functional locomotion in people with PD. However, we considered this pooled comparison to be flawed as the combination of AT/PT groups was in our view problematic given the likely differences in underlying effect sizes for these two groups in head-to-head comparisons with VR therapy. We therefore have not presented this result in table. Both reviews reporting pooled analysis rated the quality of the evidence as low to very low.

**Discussion**

**Summary of main findings**

Based on the current findings, VR therapy induced (1) increased benefits on stride/step length, balance, and neuropsychiatric symptoms as compared with AT and (2) greater effects on gait speed, stride/step length, balance, activities of daily living, and postural control as compared with PT in people with PD.
Table 4  Summary of the effectiveness of virtual reality therapy compared to passive intervention by outcomes in Parkinson’s disease

| Outcomes                     | Study                                      | Effect estimation (95 % CI) | Studies (participants) | Certainty of the evidence (GRADE) |
|------------------------------|--------------------------------------------|----------------------------|------------------------|-----------------------------------|
| Gait speed                   | Triegaardt J (2020) [19]                  | SMD 1.43 (0.51, 2.34)      | 1 (24)                 | ⊕⊕⊕⊕ Very low
| Stride/step length           | Triegaardt J (2020) [19]                  | SMD 1.27 (0.38, 2.16)      | 1 (24)                 | ⊕⊕⊕⊕ Very low
| Balance (BBS)                | Triegaardt J (2020) [19]                  | SMD 1.02 (0.38, 1.65)      | 2 (44)                 | ⊕⊕⊕ Moderate
| Balance (BBS/TUG)            | Dockx K (2016) [26]                       | SMD 1.02 (0.38, 1.65)      | 2 (44)                 | ⊕⊕⊕ Moderate
| Activities of daily living (MBI) | Triegaardt J (2020) [19]                | SMD 0.96 (0.02, 1.89)      | 1 (20)                 | ⊕⊕⊕ Moderate
| Postural control (SOT)       | Harris DM (2015) [27]                     | SMD 2.57 (1.53, 3.60)      | 1 (28)                 | ⊕⊕⊕ Moderate

CI confidence intervals, GRADE Grading of Recommendations Assessment, Development and Evaluation, SMD standard mean difference, BBS Berg balance scale, TUG Timed Up and Go test, MBI modified Barthel index, SOT sensory organization test

GRADE Working Group grades of evidence—high certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

* High risk of bias in at least a half of studies included within the analysis, hence bias is highly likely. Therefore, the certainty of evidence was downgraded by one level due to the methodological limitations (risk of bias)
* Substantial heterogeneity among trials (I² equal or more than 50%, equal or less than 90%). Therefore, the certainty of evidence was downgraded by one level (inconsistency)
* The total population size was small (<400). Therefore, the certainty of evidence was downgraded by one level (imprecision)
* High risk of bias in less than a half of studies included within the analysis, hence bias is highly likely. Therefore, the certainty of evidence was downgraded by one level due to the methodological limitations (risk of bias)
* Considerable heterogeneity among trials (I²>90%). Therefore, the certainty of evidence was downgraded by two levels (inconsistency)
* Different ways of assessment were used across studies. Therefore, the certainty of evidence was downgraded by one level (indirectness)
* The estimated effect was large reaching a plausible clinically relevant magnitude. Therefore, the certainty of evidence was upgraded by one level (other consideration, large effect)

Three reviews [16, 23, 26] formally rated the evidence using the GRADE approach and self-rated the evidence as very low quality. The remaining reviews [17–22, 24, 25, 27] did not explicitly use the GRADE approach; however, following consideration of factors such as their risk of bias appraisal results and the size of included studies, we rated them also as offering very low certainty of evidence. In addition, the overall quality of methodology of included reviews was also unsatisfactory.

We found that despite included reviews spanning decades of research, this overview was unable to offer any reliable estimate of the effect of VR therapy in terms of gait, balance, motor function, quality of life, activities of daily living, cognitive function, neuropsychiatric symptoms, and postural control.

In addition, we investigated potential causes of inconsistent results for outcome as follows: (1) Participants’ characteristics and clinical stages (Hoehn-Yahr, H&Y) may be different. Sarasso et al. [16] found the larger effect of VR-based balance training was observed in patients with greater balance deficits and disease severity (H&Y > 2) at baseline. Patients with greater balance deficits are usually in a more advanced phase of the disease, having also initial executive-attentive and visuospatial dysfunctions that could influence balance. In these patients, VR might have the potential to train both motor and cognitive domains (particularly executive-attentive and visuospatial functions) leading to a greater balance improvement. (2) Different VR modalities may be a key factor. Sarasso et al. [16] reported that VR rehabilitation-specific systems, designed and customized for a rehabilitative goal, are more effective than non-specific systems, such as commercial exergames, to improve balance in PD patients. This finding is supported by similar preliminary evidence in stroke patients [28] and gives reason for a continuous development and implementation of customizable VR systems. (3) There was high heterogeneity in outcome measures, making it difficult to make valid comparisons between different reviews. For example, activities of daily living assessed with Unified Parkinson Disease Rating Scale part II (UPDRS-II) [18, 19, 25] or modified Bartel
index (MBI) [21] did not yield consistent results even under the same comparison mode.

**Strengths and limitation of the overview**

To the best of our knowledge, our study is the first overview of SR-MAs to explore the effect of VR therapy on PD rehabilitation, which may have certain reference value for the clinical practice. In addition, the findings of this overview were based on relatively recent evidence, as all studies were published in the last 6 years. Moreover, this overview included SR-MAs of RCTs using strict inclusion standards in order to reduce the risk of bias. However, this study has several limitations. First, the methodological quality and evidence quality of the included SR-MAs were generally very low; thus, results based on primary studies should be interpreted with caution. Second, we only searched English databases, so SR-MAs published in other languages that met the inclusion criteria may have been missed. Third, there was a great heterogeneity of outcomes across the included reviews, which limited the ability to interpret overall pooled estimates. For future research, it would be necessary at least to define a homogenous outcome core set to assess the effect of VR therapy in PD patients. Fourth, the combined effects of VR therapy with any type of ATs should be compared with the same type of AT so that the additional benefits of VR therapy can be elucidated. Unfortunately, the meta-analyses often pooled trials with highly heterogeneous interventions (i.e., VR therapy/VR therapy combined with other ATs), which makes interpretation of their results very difficult. However, our overview cannot avoid this limitation and our findings must be interpreted with caution. Fifth, our overall GRADE assessment was based on a combination of assessments made by the systematic review authors and ourselves. This combination may entail inconsistency in assessments, as reliability between the assessment made by the authors of the systematic reviews and our research group is unknown. Therefore, our overview cannot avoid this limitation and our findings must be interpreted with caution.

**Conclusion**

We found the methodological quality of the reviews and the certainty of the evidence within them was poor. We were therefore unable to conclude with any confidence that, in people with PD, VR therapy is beneficial for gait, balance function, balance confidence, motor function, quality of life, activities of daily living, cognitive function, neuropsychiatric symptoms, and postural control. Rigorously-designed, high-quality RCTs with larger sample sizes are needed to further verify the effectiveness of VR therapy in the treatment of PD.

**Abbreviations**

AMSTAR-2: Assessment of Multiple Systematic Reviews 2; AT: Active intervention; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; MAs: Meta-analyses; PD: Parkinson disease; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PT: Passive interventions; RCT: Randomized controlled trials; SRs: Systematic reviews; VR: Virtual reality

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13643-022-01924-5.

---

**Acknowledgements**

The authors thank all investigators and supporters involved in this study. Especially, we would like to thank Professor Jinhui Tian (Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, China) for their valuable suggestions and inputs during the entire project. The authors thank all investigators and supporters involved in this study. Especially, we would like to thank Professor Jinhui Tian (Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, China) for their valuable suggestions and inputs during the entire project. The authors thank all investigators and supporters involved in this study. Especially, we would like to thank Professor Jinhui Tian (Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, China) for their valuable suggestions and inputs during the entire project.

---

**Authors’ contributions**

YY.S and L.Y.Q developed the initial idea for the study; G.Y.G conducted the database searches; Y.Y.S, G.Y.G, and L.Y.Q screened studies, extracted information and data from the studies, and conducted quality assessment; X.W.T conducted a bubble plot of the evidence base; Y.Y.S, G.Y.G, C.W.Q, W.L.S, and Z.C.X drafted the manuscript. L.Y.Q revised the manuscript. All authors read, critically reviewed, and approved the final manuscript as submitted.

**Funding**

None.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

**Ethics approval and consent to participate**

Ethical approval and patient consent are not required since this is an overview based on published studies.

**Consent for publication**

All authors approved the final publication of the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 18 February 2021 **Accepted:** 8 March 2022

**Published online:** 19 March 2022

**References**

1. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–5.
2. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62.
3. Tomlinson CL, Herd CP, Clarke CE, et al. Physiotherapy for Parkinson’s disease: a comparison of techniques. Cochrane Database Syst Rev. 2014;2014(6):Cd002815.
4. van der Marck MA, Mункене M, Mulleners W, et al. Integrated multidisciplinary care in Parkinson’s disease: a non-randomised, controlled trial (impact). Lancet Neurol. 2013;12(10):947–56.
5. Tambascio N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239–52.
6. Zhang C, Wang L, Hu W, et al. Combined unilateral subthalamic nucleus and contralateral globus pallidus interna deep brain stimulation for treatment of Parkinson disease: a pilot study of symptom-tailored stimulation. Neurosurgery. 2020;87(6):1139–47.

7. Canning CG, Allen NE, Nackaerts E, et al. Virtual reality in research and rehabilitation of gait and balance in Parkinson disease. Nat Rev Neurol. 2020;16(8):409–25.

8. Laver KE, Lange B, George S, et al. Virtual reality for stroke rehabilitation. Cochrane Database Syst Rev. 2017;11(11):Cd008349.

9. Parsons TD, Gaggioli A, Riva G. Virtual reality for research in social neuroscience. Brain Sci. 2017;7(4):42.

10. Maidan I, Nieuw Hof F, Bernad-Elazari H, et al. Evidence for differential effects of 2 forms of exercise on prefrontal plasticity during walking in Parkinson’s disease. Neurorehabil Neural Repair. 2018;32(3):200–8.

11. Maidan I, Rosenberg-Katz K, Jacob Y, et al. Disparate effects of training on brain activation in Parkinson disease. Neurology. 2017;89(17):1804–10.

12. Sharmaeer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed). 2015;350:g7647.

13. Higgins J, Green SR. Cochrane handbook for systematic review of interventions version 5.1.0, 2011.

14. Shea BJ, Reeves BC, Wells G, et al. AmSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical research ed). 2017;358:j4008.

15. Pollock A, Farmer SE, Brady MC, et al. An algorithm was developed to assign grade levels of evidence to comparisons within systematic reviews. J Clin Epidemiol. 2016;70:106–10.

16. Sarasso E, Gaidoni A, Tettamanti A, et al. Virtual reality balance training to improve balance and mobility in Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2021. [Epub ahead of print].

17. Li R, Zhang Y, Jiang Y, et al. Rehabilitation training based on virtual reality for patients with Parkinson’s disease in improving balance, quality of life, activities of daily living, and depressive symptoms: a systematic review and meta-regression analysis. Clin Rehabil. 2021;35(8):1089–102.

18. Elena P, Demetris S, Christina M, et al. Differences between exergaming rehabilitation and conventional physiotherapy on quality of life in Parkinson’s disease: a systematic review and meta-analysis. Front Neurol. 2021;12.

19. Triegaardt J, Han TS, Sada C, et al. The role of virtual reality on outcomes in rehabilitation of Parkinson’s disease: meta-analysis and systematic review in 1031 participants. Neurol Sci. 2020;41(3):529–36.

20. Marotta N, Demeco A, Indino A, et al. Nintendo Wii™ versus Xbox Kinect™ for functional locomotion in people with Parkinson’s disease: a systematic review and network meta-analysis. Disabil Rehabil. 2020. [Epub ahead of print].

21. Lina C, Guoen C, Huidan W, et al. The effect of virtual reality on the ability to perform activities of daily living, balance during gait, and motor function in Parkinson disease patients: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2020;99(10):917–24.

22. Chen Y, Gao Q, He CQ, et al. Effect of virtual reality on balance in individuals with Parkinson disease: a systematic review and meta-analysis of randomized controlled trials. Phys Ther. 2020;100(6):933–45.

23. Wang B, Shen M, Wang YX, et al. Effect of virtual reality on balance and gait ability in patients with Parkinson disease: A systematic review and meta-analysis. Clin Rehabil. 2019;33(7):1130–8.

24. Santos P, Scaldaferrari G, Santos L, et al. Effects of the Nintendo Wii training on balance rehabilitation and quality of life of patients with Parkinson’s disease: a systematic review and meta-analysis. Neurorehabil. 2019;34(4):569–77.

25. Lei C, Sunzi K, Dai F, et al. Effects of virtual reality rehabilitation training on gait and balance in patients with Parkinson’s disease: a systematic review. PLoS One. 2019;14(11).

26. Dockx K, Bekkers EM, Van den Bergh Y, et al. Virtual reality for rehabilitation in Parkinson’s disease. Cochrane Database Syst Rev. 2016;12(2):Cd010760.

27. Harris DM, Rantalainen T, Muthalib M, et al. Exergaming as a viable therapeutic tool to improve static and dynamic balance among older adults and people with idiopathic Parkinson’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2015;7(SEP).

28. Sarasso E, Agosta F, Temporiti F, et al. Brain motor functional changes after somatosensory discrimination training. Brain Imaging Behav. 2018;12(4):1011–21.